The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer

Immunotherapy encourages the recipient’s own immune response to destroy cancer cells, and current evidence suggests that immunotherapies may be most beneficial in early metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T is the first therapeutic cancer vaccine to be approved by bot...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Mouraviev, Vladimir, Mariados, Neil, Albala, David, Concepcion, Raoul S, Shore, Neal D, Sims, Robert B, Emberton, Mark, Pieczonka, Christopher M
Format: Artigo
Jezik:Inglês
Izdano: MedReviews, LLC 2014
Teme:
Treatment Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4191632/
https://ncbi.nlm.nih.gov/pubmed/25337042
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items